Qin Xuan, Shi Haoliang, Li Hongyang, Chu Binbin, Zhang Jiawei, Wen Zhen, Sun Xuhui, Wang Houyu, He Yao
Suzhou Key Laboratory of Nanotechnology and Biomedicine, Institute of Functional Nano & Soft Materials & Collaborative Innovation Center of Suzhou Nano Science and Technology (NANO-CIC), Soochow University, Suzhou, China.
Macao Translational Medicine Center, Macau University of Science and Technology, Taipa, Macau, SAR, China.
Nat Commun. 2025 Jan 2;16(1):33. doi: 10.1038/s41467-024-55336-1.
Current treatments for fundus disorders, such as intravitreal injections, pose risks, including infection and retinal detachment, and are limited in their ability to deliver macromolecular drugs across the blood‒retinal barrier. Although non-invasive methods are safer, their delivery efficiency remains suboptimal (<5%). We have developed a wearable electrodriven switch (WES) that improves the non-invasive delivery of macromolecules to the fundus. The WES system, which integrates an electrodriven drug delivery lens with a square wave generator, leverages electrical stimulation to enhance drug penetration through the sclera-choroid-retina pathway. In our study, WES achieved a delivery efficiency of 14% for immunoglobulin G, comparable to that of intravitreal injection (16%). Moreover, WES-enhanced anti-VEGF administration resulted in an 86% inhibition of choroidal neovascularization, and anti-PDL1 delivery inhibited choroidal melanoma growth more effectively than intravenous injections, with no adverse effects on ocular health. These findings suggest that WES holds transformative potential for the non-invasive treatment of chronic fundus diseases.
目前针对眼底疾病的治疗方法，如玻璃体内注射，存在包括感染和视网膜脱离在内的风险，并且在跨越血视网膜屏障递送大分子药物的能力方面存在局限。尽管非侵入性方法更安全，但其递送效率仍然欠佳（<5%）。我们开发了一种可穿戴式电驱动开关（WES），它能提高大分子向眼底的非侵入性递送。WES系统将一个电驱动药物递送透镜与一个方波发生器集成在一起，利用电刺激来增强药物通过巩膜-脉络膜-视网膜途径的渗透。在我们的研究中，WES对免疫球蛋白G的递送效率达到了14%，与玻璃体内注射（16%）相当。此外，WES增强的抗VEGF给药导致脉络膜新生血管形成受到86%的抑制，并且抗PDL1递送比静脉注射更有效地抑制脉络膜黑色素瘤生长，对眼部健康没有不良影响。这些发现表明，WES在慢性眼底疾病的非侵入性治疗方面具有变革潜力。
